Dekkers O M, Pereira A M, Roelfsema F, Voormolen J H C, Neelis K J, Schroijen M A, Smit J W A, Romijn J A
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
J Clin Endocrinol Metab. 2006 May;91(5):1796-801. doi: 10.1210/jc.2005-2552. Epub 2006 Feb 28.
Transsphenoidal surgery is the treatment of choice for nonfunctioning pituitary macroadenomas (NFMA). In this study we evaluated the long-term effects of a treatment strategy in which postoperative radiotherapy was not routinely applied to patients with NFMA.
This was a retrospective follow-up study.
We included 109 consecutive patients (age 56 +/- 13 yr) operated for NFMA between 1992 and 2004.
Radiological imaging revealed a macroadenoma in all patients, with suprasellar extension in 96% and parasellar/infrasellar extension in 36% of cases. Visual field defects were present in 87% of the patients and improved in 84% of these patients after surgery. Only six patients received postoperative radiotherapy. Ten patients died during the follow-up period. Ninety-seven patients could be assessed for tumor regrowth or tumor recurrence after a mean follow-up period of 6.0 +/- 3.7 yr. In nine patients there was evidence for tumor regrowth, and in one patient tumor recurrence was observed. The mean time to tumor growth/recurrence after initial therapy was 6.9 (range 3-12) yr. Follow-up duration was found to be an independent predictor for tumor regrowth.
Transsphenoidal surgery without postoperative radiotherapy is an effective and safe treatment strategy for NFMA, without evidence for tumor regrowth in 90% of all patients, at least for the duration of follow-up presented in this study. Additional studies are required to exclude higher regrowth and recurrence rates during prolongation of the duration of follow-up.
经蝶窦手术是无功能垂体大腺瘤(NFMA)的首选治疗方法。在本研究中,我们评估了一种治疗策略的长期效果,即对NFMA患者不常规应用术后放疗。
这是一项回顾性随访研究。
我们纳入了1992年至2004年间连续接受NFMA手术的109例患者(年龄56±13岁)。
影像学检查显示所有患者均为大腺瘤,96%的病例有鞍上扩展,36%的病例有鞍旁/鞍下扩展。87%的患者存在视野缺损,其中84%的患者术后视野缺损有所改善。仅6例患者接受了术后放疗。10例患者在随访期间死亡。97例患者在平均随访6.0±3.7年之后可评估肿瘤再生长或肿瘤复发情况。9例患者有肿瘤再生长的证据,1例患者观察到肿瘤复发。初始治疗后肿瘤生长/复发的平均时间为6.9年(范围3 - 12年)。随访时间被发现是肿瘤再生长的独立预测因素。
对于NFMA,不进行术后放疗的经蝶窦手术是一种有效且安全的治疗策略,至少在本研究呈现的随访期间,90%的患者没有肿瘤再生长的证据。需要进一步研究以排除随访时间延长期间更高的再生长和复发率。